Advertisement
- United States
- /
- Biotech
- /
- NasdaqGS:CCCC
C4 Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
C4 Therapeutics (NASDAQ:CCCC) Full Year 2024 Results
Key Financial Results
- Revenue: US$35.6m (up 71% from FY 2023).
- Net loss: US$105.3m (loss narrowed by 21% from FY 2023).
- US$1.52 loss per share (improved from US$2.67 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
C4 Therapeutics EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.6%.
Looking ahead, revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 13% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for C4 Therapeutics that you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:CCCC
C4 Therapeutics
A clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Flawless balance sheet and slightly overvalued.
Market Insights
Advertisement
Weekly Picks
JO
Jolt_Communications on Myseum ·
The Future of Social Sharing Is Private and People Are Ready
Fair Value:US$7.9576.7% undervalued
37 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
TO
Tokyo on ASML Holding ·
EU#3 - From Philips Management Buyout to Europe’s Biggest Company
Fair Value:€1.31k9.0% undervalued
32 followersusers have followed this narrative
4 commentsusers have commented on this narrative
12 likesusers have liked this narrative
YI
yiannisz on Booking Holdings ·
Booking Holdings: Why Ground-Level Travel Trends Still Favor the Platform Giants
Fair Value:US$5.47k15.0% undervalued
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
4 likesusers have liked this narrative
CO
composite32 on Shell ·
A fully integrated LNG business seems to be ignored by the market.
Fair Value:UK£36.122.7% undervalued
40 followersusers have followed this narrative
0 commentsusers have commented on this narrative
9 likesusers have liked this narrative
Recently Updated Narratives
RE
RecMag on Proximus ·
Proximus: The State-Backed Backup Plan with 7% Gross Yield and 15% Currency Upside.
Fair Value:€17.1354.8% undervalued
37 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
CO
composite32 on SEGRO ·
SEGRO's Revenue to Rise 14.7% Amidst Optimistic Growth Plans
Fair Value:UK£9.3918.8% undervalued
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AL
alex30free on Beijer Ref ·
The Green Consolidator
Fair Value:SEK 128.821.0% overvalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
WE
WealthAP on PayPal Holdings ·
The "Sleeping Giant" Stumbles, Then Wakes Up
Fair Value:US$8249.1% undervalued
85 followersusers have followed this narrative
6 commentsusers have commented on this narrative
35 likesusers have liked this narrative
OO
OOO97 on Neo Performance Materials ·
Undervalued Key Player in Magnets/Rare Earth
Fair Value:CA$25.3320.9% undervalued
75 followersusers have followed this narrative
0 commentsusers have commented on this narrative
19 likesusers have liked this narrative
AN
AnalystConsensusTarget on NVIDIA ·
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$253.0228.7% undervalued
1050 followersusers have followed this narrative
6 commentsusers have commented on this narrative
31 likesusers have liked this narrative
Trending Discussion
HE
Hemingway on Aeva Technologies ·
NVDA+AEVA Agreement is a game changer for the AEVA stock even though it is just a partnership and does not have a roll out until 2028 (which means receivables as early as 2027, I would imagine) This agreement effectively moves the goal posts of profitability for AEVA much closer since this is in addition to the recent Forterra agreement, as well as the (previously announced) European carmaker agreement (which is believed to be Mercedes-Benz and estimated to be worth at least 1 billion in sales alone) Underneath all of this, AEVA has a pre-existing agreement with Daimler Truck. So business seems to be booming, especially with really big name brands…which tends to bring in even more brand names (and thus more agreements/contracts/announcements, etc). This dynamic often creates more coverage from analysts (often with upside stock initial coverage) that I believe will be occurring over the next 3 to 6 months (as professional traders/analysts often research for 2 to 3 months before initiating coverage of a new issue). I also feel that the above momentum increases the likelihood that companies that do not currently utilize 4G LIDAR technology might consider buying AEVA outright. Realistically, even with a substantial premium to the current stock price, the cost of AEVA would be a rounding error for the likes of a company such as Tesla, and certainly would allow them to maintain their technological edge as the competition for self-driving vehicles continues to heat up. However, I think it is equally possible for NVidea to decide to lock-in the AEVA technology for their upcoming autonomous hardware/software package by buying them outright. Obviously, the above factors and recent activity in the AEVA stock are cause for optimism. Of course, this all just one opinion , so please do your own due diligence. Disclaimer: I/We DO trade in this stock from time to time and I/we may (or may not have) a position currently, so again, please do your own due diligence.
0
|0
